$EXEL News

Wells Fargo Maintains Equal-Weight on Exelixis, Raises Price Target to $49

Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued?

Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run

Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely

Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In?

Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?

RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $46

Truist Securities Maintains Hold on Exelixis, Raises Price Target to $56

Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says

UBS Maintains Neutral on Exelixis, Raises Price Target to $52

HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $56 Price Target

Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector

Truist Securities Downgrades Exelixis to Hold, Raises Price Target to $54

Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $55

Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC

Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions

Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?

Exelixis Hits High on Growing Sales, Institutional Inflows